Home/Pipeline/SHR-A1811

SHR-A1811

HER2+ Solid Tumors

Phase IIIActiveNCT05952522

Key Facts

Indication
HER2+ Solid Tumors
Phase
Phase III
Status
Active
Company

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.

View full company profile